EA202090398A1 - Фармацевтическая композиция, включающая сакубитрил и валсартан - Google Patents

Фармацевтическая композиция, включающая сакубитрил и валсартан

Info

Publication number
EA202090398A1
EA202090398A1 EA202090398A EA202090398A EA202090398A1 EA 202090398 A1 EA202090398 A1 EA 202090398A1 EA 202090398 A EA202090398 A EA 202090398A EA 202090398 A EA202090398 A EA 202090398A EA 202090398 A1 EA202090398 A1 EA 202090398A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
valsartan
sakubitril
relates
present
Prior art date
Application number
EA202090398A
Other languages
English (en)
Inventor
Бохумил Димацек
Марта Виванкос Мартинес
Луис Ногейрас Ньето
Лисардо Альварес Фернандес
Рохит Кумар
Хосе Велада Кальсада
Петр Миташ
Original Assignee
Синтон Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтон Б.В. filed Critical Синтон Б.В.
Publication of EA202090398A1 publication Critical patent/EA202090398A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Настоящее изобретение относится к фармацевтической композиции, включающей физическую смесь натриевой соли сакубитрила и динатриевой соли валсартана, где порошковая рентгеновская дифрактограмма динатриевой соли валсартана включает характеристические пики при следующих углах 2 тета (0,2): 4,70, 9,29, 22,34°, измеренные с использованием излучения Cu K. Настоящее изобретение также относится к применению указанной фармацевтической композиции в качестве лекарственного средства для лечения сердечной недостаточности.
EA202090398A 2017-07-28 2018-07-25 Фармацевтическая композиция, включающая сакубитрил и валсартан EA202090398A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183859 2017-07-28
PCT/EP2018/070212 WO2019020706A1 (en) 2017-07-28 2018-07-25 PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN

Publications (1)

Publication Number Publication Date
EA202090398A1 true EA202090398A1 (ru) 2020-05-15

Family

ID=59501295

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090398A EA202090398A1 (ru) 2017-07-28 2018-07-25 Фармацевтическая композиция, включающая сакубитрил и валсартан

Country Status (6)

Country Link
US (1) US10588892B2 (ru)
EP (1) EP3658122B1 (ru)
EA (1) EA202090398A1 (ru)
ES (1) ES2881317T3 (ru)
PL (1) PL3658122T3 (ru)
WO (1) WO2019020706A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
EP4088715A1 (en) 2021-05-14 2022-11-16 KRKA, d.d., Novo mesto Pharmaceutical formulation of valsartan and sacubitril
WO2023211412A1 (en) * 2022-04-26 2023-11-02 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising sacubitril and valsartan processed with dry granulation
EP4268806A3 (en) * 2022-04-26 2023-12-27 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising sacubitril and valsartan processed with dry granulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
BR122018015003B8 (pt) 2002-01-17 2021-07-27 Novartis Ag kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CA2703598C (en) 2007-11-06 2016-08-09 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
WO2013181455A1 (en) * 2012-05-30 2013-12-05 Robert Gellibolian Water bottle with flow meter
CN105837464A (zh) 2015-01-15 2016-08-10 四川海思科制药有限公司 沙库比曲钠的晶型及其制备方法和用途
KR20200117037A (ko) * 2015-06-12 2020-10-13 테바 파마슈티컬스 인터내셔널 게엠베하 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
EP3386945A1 (en) * 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds

Also Published As

Publication number Publication date
EP3658122B1 (en) 2021-04-07
EP3658122A1 (en) 2020-06-03
PL3658122T3 (pl) 2021-10-18
US20190030000A1 (en) 2019-01-31
WO2019020706A1 (en) 2019-01-31
ES2881317T3 (es) 2021-11-29
US10588892B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
EA202090398A1 (ru) Фармацевтическая композиция, включающая сакубитрил и валсартан
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2020011818A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12016502353A1 (en) Pharmaceutical composition
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201692298A1 (ru) Производные карбоксамидов
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
PH12015501945A1 (en) Formulations of organic compounds
MX2020012336A (es) Formulacion farmaceutica.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2009008176A (es) Derivados de tetrahidro-naftaleno sustituidos con heterociclos, su preparacion y su uso como medicamentos.
MY197042A (en) Compounds
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals